Ethanesulfonyl-piperidine derivatives
    65.
    发明授权
    Ethanesulfonyl-piperidine derivatives 有权
    乙磺酰基 - 哌啶衍生物

    公开(公告)号:US06310213B1

    公开(公告)日:2001-10-30

    申请号:US09585755

    申请日:2000-06-02

    IPC分类号: C07D21120

    CPC分类号: C07D211/46 C07D211/14

    摘要: The invention relates to compounds of the general formula wherein R1 signifies hydrogen or hydroxy; R2 signifies hydrogen or methyl; and X signifies —O— or —CH2— and their pharmaceutically acceptable acid addition salts. It has been shown that these compounds have a good affitity to the NMDA receptor and they are therefore useful in the treatment of diseases, wherein the therapeutic indications include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and, diseases such as schizophrenia, anxiety, depression and chronic/acute pain.

    摘要翻译: 本发明涉及一般化学式R 1表示氢或羟基的化合物; R2表示氢或甲基; 并且X表示-O-或-CH 2 - 及其药学上可接受的酸加成盐。已经显示这些化合物对NMDA受体具有良好的依赖性,因此它们可用于治疗疾病,其中治疗适应症包括急性 形成神经退行性疾病,例如中风或脑外伤; 慢性形式的神经变性如阿尔茨海默病,帕金森病,亨廷顿病或ALS(肌萎缩性侧索硬化); 与细菌或病毒感染相关的神经变性,以及精神分裂症,焦虑症,抑郁症和慢性/急性疼痛等疾病。

    Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative
    66.
    发明授权
    Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative 失效
    通过施用芳基环己胺衍生物治疗神经变性疾病的方法

    公开(公告)号:US06184236B2

    公开(公告)日:2001-02-06

    申请号:US09370602

    申请日:1999-08-09

    IPC分类号: A61K31445

    摘要: The present invention provides a method of treatment of a disease associated with neurodegeneration by administering a therapeutically effective amount of a compound of the general formula wherein Ar1 is phenyl, naphthyl or tetrahydronaphthyl, optionally substituted by hydroxy, lower alkoxy, nitro, amino or methanesulfonamide; Ar2 is phenyl, naphthyl or tetrahydronaphthyl, optionally substituted by lower alkyl or halogen; X is C, CH, C(OH) or N; Y is —CH2−, CH or O; Z —CH2—, —CH(CH3)— or —C(CH3)2—; R1 is hydrogen, lower alkyl or acetyl; A is C═O or —(CHR2)n—, wherein R2 is hydrogen, lower alkyl or hydroxy-lower alkyl; B is —(CH2)n—, O, —CH(OH)(CH2)n—, —CH(CH2OH)(CH2)n—, —(CH2)n CH(OH)— or —CH(CH2OH)—; - - - may be a bond; and n is 0-4, or pharmaceutically acceptable acid addition salts thereof.

    摘要翻译: 本发明提供治疗与神经退行性疾病相关的疾病的方法,其通过施用治疗有效量的通式化合物,其中Ar 1是任选被羟基,低级烷氧基,硝基,氨基或甲磺酰胺取代的苯基,萘基或四氢萘基; Ar 2是 苯基,萘基或四氢萘基,任选被低级烷基或卤素取代; X是C,CH,C(OH)或N; Y是-CH 2 - ,CH或O; Z -CH 2 - , - CH(CH 3) C(CH 3)2 - ; R 1是氢,低级烷基或乙酰基; A是C = O或 - (CHR 2)n - ,其中R 2是氢,低级烷基或羟基 - 低级烷基; B是 - (CH 2) ,O,-CH(OH)(CH 2)n - , - CH(CH 2 OH)(CH 2)n - , - (CH 2)n CH(OH) - 或-CH(CH 2 OH) - ; - - ; andn为0-4,或其药学上可接受的酸加成盐。